Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting
Open Access
- 3 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (5), 1063-1071
- https://doi.org/10.1007/s10096-021-04169-7
Abstract
Evaluation and power of seroprevalence studies depend on the performed serological assays. The aim of this study was to assess four commercial serological tests from EUROIMMUN, DiaSorin, Abbott, and Roche as well as an in-house immunofluorescence and neutralization test for their capability to identify SARS-CoV-2 seropositive individuals in a high-prevalence setting. Therefore, 42 social and working contacts of a German super-spreader were tested. Consistent with a high-prevalence setting, 26 of 42 were SARS-CoV-2 seropositive by neutralization test (NT), and immunofluorescence test (IFT) confirmed 23 of these 26 positive test results (NT 61.9% and IFT 54.8% seroprevalence). Four commercial assays detected anti-SARS-CoV-2 antibodies in 33.3-40.5% individuals. Besides an overall discrepancy between the NT and the commercial assays regarding their sensitivity, this study revealed that commercial SARS-CoV-2 spike-based assays are better to predict the neutralization titer than nucleoprotein-based assays are.Keywords
Funding Information
- Jürgen Manchot Stiftung
- Heinz-Ansmann Foundation for AIDS Research
This publication has 25 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donorsPublished by Cold Spring Harbor Laboratory ,2020
- Cluster of COVID-19 in northern France: A retrospective closed cohort studyPublished by Cold Spring Harbor Laboratory ,2020
- Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implicationsPublished by Cold Spring Harbor Laboratory ,2020
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Serum Virus Neutralization Assay for Detection and Quantitation of Serum-Neutralizing Antibodies to Influenza A Virus in SwinePublished by Springer Science and Business Media LLC ,2014
- Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologymAbs, 2010